<DOC>
	<DOCNO>NCT00762073</DOCNO>
	<brief_summary>This randomize , placebo-controlled , parallel-arm , dose-ranging study subject eosinophilic esophagitis , 2-18 year age . Eligible subject randomize one four treatment group . The Treatment Period 12 week subject visit clinic study week 0 ( Baseline Visit ) , 2 , 4 , 8 12 ( Final Treatment Evaluation ) clinical symptom assessment safety evaluation ( include adverse event vital sign ) . All study treatment ( active drug placebo ) administer orally twice daily Treatment Period , morning breakfast evening bedtime .</brief_summary>
	<brief_title>Dose-Ranging Study Oral Viscous Budesonide Pediatrics With Eosinophilic Esophagitis</brief_title>
	<detailed_description />
	<mesh_term>Esophagitis</mesh_term>
	<mesh_term>Eosinophilic Esophagitis</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<criteria>Male female subject age 218 year , inclusive History clinical symptom esophageal dysfunction intermittently continuously Histologic evidence EoE peak eosinophil count great equal 20 eosinophil per HPF , two level esophagus , within six week prior Baseline Visit At Baseline Visit , subject must symptoms total EoE Clinical Symptom Score great equal 3 Willingness ability continue dietary therapy , environmental therapy , and/or medical regimen ( include gastric acid suppression , ) effect Screening Visit Females childbearing potential must negative serum pregnancy test ( beta human chorionic gonadotropin ) prior randomization study sexually active subject must agree continue acceptable birth control measure throughout duration study Written inform consent ( parent legal guardian ) , appropriate , subject assent Current use immunomodulatory therapy ( anticipate use within 12 week follow Baseline Visit ) Diagnosis inflammatory bowel disease Chronic viral infection immunodeficiency condition ( current ) Use swallow topical corticosteroid EoE 1 month prior biopsy require entrance study time biopsy Baseline Visit Use systemic ( oral parenteral ) corticosteroid within 1 month prior biopsy require entrance study time biopsy Baseline Visit Morning plasma cortisol level lower limit normal ( per Central Laboratory reference range ) Screening Visit Upper gastrointestinal bleeding within 1 month prior Screening Visit Screening Visit Baseline Visit Current use anticoagulant Current disease gastrointestinal tract aside current EoE diagnosis Evidence concurrent eosinophilic gastritis , enteritis , colitis , proctitis Evidence active infection Helicobacter pylori Evidence unstable asthma change asthma allergic rhinitis therapy within 1 month prior biopsy require entrance study Any female pregnant , plan become pregnant , breastfeed Current evidence history hypersensitivity idiosyncratic reaction budesonide ingredient study medication Current evidence oropharyngeal esophageal candidiasis Receipt investigational drug within 30 day prior biopsy require entrance study Any condition abnormality , opinion Principal Investigator , would compromise safety subject successful conduct study</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>eosinophilic esophagitis</keyword>
</DOC>